Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Welprid M
Welprid M is a dual-action oral antidiabetic therapy containing Glimepiride and Metformin, specifically formulated for patients with type 2 diabetes mellitus (T2DM). This combination effectively targets insulin resistance and pancreatic beta-cell dysfunction, ensuring better glycemic control while reducing the risk of diabetes-related complications.
Uses of Welprid M
Welprid M is indicated for the management of:
Type 2 diabetes mellitus (T2DM)
Poorly controlled blood sugar levels despite diet and exercise
Patients requiring combination therapy for enhanced glucose control
Benefits of Welprid M
Dual Mechanism for Optimal Glycemic Control: Stimulates insulin secretion and enhances insulin sensitivity
Reduces Hepatic Glucose Production: Lowers fasting blood glucose levels
Improves Postprandial Glucose Regulation: Reduces glucose spikes after meals
Minimizes Risk of Hypoglycemia: Balanced approach for stable blood sugar levels
Prevents Long-Term Diabetes Complications: Supports cardiovascular and metabolic health
Mechanism of Action of Welprid M
Glimepiride (Sulfonylurea): Stimulates pancreatic beta cells to increase insulin secretion, enhancing glucose uptake by tissues.
Metformin (Biguanide): Decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose utilization.